Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer.

Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Abstract Text:

PURPOSE: To investigate the potential effect of using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer. METHODS AND MATERIALS: During 14 consecutive months, 39 patients (40 tumors) who presented with Stage II or III breast cancer on the basis of a routine extension assessment were prospectively included in this study. PET/CT was performed in addition to the initial assessment. RESULTS: In 3 cases, PET/CT showed extra-axillary lymph node involvement that had not been demonstrated with conventional techniques. Two of these patients had hypermetabolic lymph nodes in the subpectoral and infraclavicular regions, and the third had a hypermetabolic internal mammary node. PET/CT showed distant uptake in 4 women. Of these 4 women, 1 had pleural involvement and 3 had bone metastasis. Overall, of the 39 women, the PET/CT results modified the initial stage in 7 (18%). The modified staging altered the treatment plan for 5 patients (13%). It led to radiotherapy in 4 patients (bone metastasis, pleural lesion, subpectoral lymph nodes, and internal mammary nodes) and excision of, and radiotherapy to, the infraclavicular lymph nodes in 1 patient. CONCLUSIONS: PET/CT can provide information on extra-axillary lymph node involvement and can uncover occult distant metastases in a significant percentage of patients. Therefore, initial PET/CT could enable better treatment planning for patients with Stage II and III breast cancer.

Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of radiation oncology, biolo

VOLUME: 71

Page Numbers: 695-704

Journal Abbreviation: Int. J. Radiat. Oncol. Biol. P

ISSN: 0360-3016

DAY: 23

MONTH: 04

YEAR: 2008

Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603616

Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer.

AFFILIATION: Department of Nuclear Medicine, Breast Diseases Unit, Saint Louis Hospital, Paris, France.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Radiat Oncol Biol Phys

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer Related Publications

• A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.
• Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer.